Karyopharm - oncology

Quote
Most posters on here are shareholders that don’t understand a few things about biotech and want to cast blame for their own mismanagement of their portfolio on others.

1) biotechs outcomes are very binary
2) the path to FDA is long and unpredictable
3) cash burn is always high
4) don’t put all your eggs in one biotech basket
5) more common sense
 












anonymous said:
Most posters on here are shareholders that don’t understand a few things about biotech and want to cast blame for their own mismanagement of their portfolio on others.

1) biotechs outcomes are very binary
2) the path to FDA is long and unpredictable
3) cash burn is always high
4) don’t put all your eggs in one biotech basket
5) more common sense
Click to expand...
Oh yeah, blame the investor for gross negligence of CEO. That sounds wise. It’s irrelevant whether this stock fits the “right portfolio”. No shit biotech is risky,
I had many go to zero and others go to 100 ps from 2 ps. Usually a commercially approved drug is over the hump to make a go of it. RP was handed that and still fucked it up. He thought S1
Was stat signed until the junior analyst had to correct him on the call. He never recovered from that defrocking. But yeah, it’s then investor’s fault entirely from believing all his over hype bullshit about 4 pillars and new stage of growth and unprecedented high unmet needs. lol. Yes it’s our fault 100 percent and that is why I vote my 200k as an investor to say fuck no to all special meeting items. No to r/s no to share expansion. Just go die and be done with it. I’ll accept my lose and move on but why should be give RP and the goofs a new lease on life to bleed for another year. Bk is coming whether it’s now or 18 month. F him and his Canadian pony
 






anonymous said:
Oh yeah, blame the investor for gross negligence of CEO. That sounds wise. It’s irrelevant whether this stock fits the “right portfolio”. No shit biotech is risky,
I had many go to zero and others go to 100 ps from 2 ps. Usually a commercially approved drug is over the hump to make a go of it. RP was handed that and still fucked it up. He thought S1
Was stat signed until the junior analyst had to correct him on the call. He never recovered from that defrocking. But yeah, it’s then investor’s fault entirely from believing all his over hype bullshit about 4 pillars and new stage of growth and unprecedented high unmet needs. lol. Yes it’s our fault 100 percent and that is why I vote my 200k as an investor to say fuck no to all special meeting items. No to r/s no to share expansion. Just go die and be done with it. I’ll accept my lose and move on but why should be give RP and the goofs a new lease on life to bleed for another year. Bk is coming whether it’s now or 18 month. F him and his Canadian pony
Click to expand...
One of the issues (admittedly among many) with RP is that’s he’s incredibly lazy. He’s never been willing to do the work that’s required.
 






This CEO thought he was running Amgen not shittyyopharm. We would never be in this spot if he exercised a little foresight and strategy. He believed his own bullshit too much to allow for prudence. Did he really think S2 would readout in 2nd half 25 or first half 25 ?? Really…..did he really believe running trial with a where patient ts may get placebo would yield a quick uptake in enrollment, really??? This guy and the chick are supposed to be pros, yet time and again they reveal quite the opposite. I agree with the other poster about NO to all items at meeting. Sorry, time is up. I’d rather just keep shorting the stock where this CEO and CMO land. That seems the most profitable strategy. Happy new year yall from TN
 






anonymous said:
Oh yeah, blame the investor for gross negligence of CEO. That sounds wise. It’s irrelevant whether this stock fits the “right portfolio”. No shit biotech is risky,
I had many go to zero and others go to 100 ps from 2 ps. Usually a commercially approved drug is over the hump to make a go of it. RP was handed that and still fucked it up. He thought S1
Was stat signed until the junior analyst had to correct him on the call. He never recovered from that defrocking. But yeah, it’s then investor’s fault entirely from believing all his over hype bullshit about 4 pillars and new stage of growth and unprecedented high unmet needs. lol. Yes it’s our fault 100 percent and that is why I vote my 200k as an investor to say fuck no to all special meeting items. No to r/s no to share expansion. Just go die and be done with it. I’ll accept my lose and move on but why should be give RP and the goofs a new lease on life to bleed for another year. Bk is coming whether it’s now or 18 month. F him and his Canadian pony
Click to expand...

Regardless of how you vote, all measures will be approved. You can complain all you want, but the majority of voting shares are always behind the management team and board.
 












This CEO will fail if he given 1 more year…..3 more years…..or 10 more years. He started with four potential targets1. Mm all oral. 2. MDs 3. Mf and 4. Endo. Look at the results for each. All oral can’t get to readout due to shitty enrollment. But blame that on competition in that space lol. MDS this carrot was dangled and hyped as the holy grail. They talked this up like they discovered fire. Not. It got shelved bc results were, how do u say meh. Forget that anyway we have Endo and 40 months of
Pfs. We can’t get AA bc we fucked up trial design of S1. But look at pmmr, it is amazing. Why did it die on the vine then???? Come on, do we even need to keep going???? Lmfao
 






anonymous said:
This CEO will fail if he given 1 more year…..3 more years…..or 10 more years. He started with four potential targets1. Mm all oral. 2. MDs 3. Mf and 4. Endo. Look at the results for each. All oral can’t get to readout due to shitty enrollment. But blame that on competition in that space lol. MDS this carrot was dangled and hyped as the holy grail. They talked this up like they discovered fire. Not. It got shelved bc results were, how do u say meh. Forget that anyway we have Endo and 40 months of
Pfs. We can’t get AA bc we fucked up trial design of S1. But look at pmmr, it is amazing. Why did it die on the vine then???? Come on, do we even need to keep going???? Lmfao
Click to expand...
The best part is the misleading refrain for last 18 months is that “we have enough cash to get to readouts”. How many times did he utter those words. He said it so many times that the cfo shit his pants and resigned for fear of getting sued.
 
















































The Securities and Exchange Commission today charged XXXXXXX XXXXXXX, the former CEO of XXXXXXXX Inc, with fraud and insider training in connection with providing misleading information to shareholders about the progress of a clinical research treatment for XXXXXXXX.

According to the SEC's complaint, XXXXXXX XXXXXXX repeatedly issued press releases exaggerating XXXXXXXXXXX’s progress with regard to XXXXXXX. The complaint alleges that in an XXX 202X press release, falsely announced that the company had submitted a completed Application to the U.S. Food and Drug Administration-a key milestone that caused the company's stock price to increase. As set forth in the complaint, the FDA submission was woefully inadequate, and the FDA alerted the company of those deficiencies within days, however, XXXXXXX XXXXXXX did not alert shareholders to this information. In the meantime, XXXXXXX allegedly sold approximately $X.X million worth of XXXXXXXXXX stock based on the false information, netting profits of more than $X.X million.
 


















Top Bottom
Back
Quote